Bacillus subtilis spores as vaccine adjuvants: Further insights into the mechanisms of action

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  De Souza, Renata Damásio ^a   Batista, Milene Tavares ^a   Luiz, Wilson Barros ^a   Cavalcante, Rafael Ciro Marques ^a   Amorim, Jaime Henrique ^a   Bizerra, Raíza Sales Pereira ^a   Martins, Eduardo Gimenes ^a   De Souza Ferreira, Luís Carlos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CAPSID PROTEIN; CD40 ANTIGEN; CYTOKINE; GAG PROTEIN; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN; MYELOID DIFFERENTIATION FACTOR 88; RECOMBINANT ANTIGEN; TOLL LIKE RECEPTOR 2;

ADAPTIVE IMMUNITY; ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ARTICLE; BACILLUS SUBTILIS; BACTERIAL GENETICS; BACTERIAL SPORE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; MOUSE; NONHUMAN; UPREGULATION;

ADJUVANTS, PHARMACEUTIC; ANALYSIS OF VARIANCE; ANIMALS; BACILLUS SUBTILIS; FLOW CYTOMETRY; HIV CORE PROTEIN P24; IMMUNITY, CELLULAR; INFUSIONS, PARENTERAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; SPORES, BACTERIAL; TOLL-LIKE RECEPTOR 2; VACCINES;

EID: 84900329188     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087454     Document Type: Article

References (33)

1. Reed SG, Bertholet S, Coler RN, Friede M (2008) New horizons in adjuvants for vaccine development. Trends Immunol 30: 23-32.
2. Lambrecht BN, Kool M, Willart MA, Hammad H (2009) Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 21: 23-29.
3. O'Hagan DT, Valiante NM (2003) Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2: 727-735. (Pubitemid 37361788)
4. Montomoli E, Piccirella S, Khadang B, Mennitto E, Camerini R, et al. (2011) Current adjuvants and new perspectives in vaccine formulation. Expert Rev Vaccines 10: 1053-1061.
5. Heegaard PM, Dedieu L, Johnson N, Le Potier MF, Mockey M, et al. (2011) Adjuvants and delivery systems in veterinary vaccinology: current state and future developments. Arch Virol 156: 183-202.
6. Miyaji EN, Carvalho E, Oliveira ML, Raw I, Ho PL (2011) Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants. Braz J Med Biol Res 44: 500-513.
7. Huang JM, Hong HA, VanTong H, Hoang TH, Brisson A, et al. (2010) Mucosal delivery of antigens using adsorption to bacterial spores. Vaccine 28: 1021-1030.
8. Barnes AGC, Cerovic V, Hobson PS, Klavinskis LS (2007) Bacillus subtilis spores: a novel microparticle adjuvant which can instruct a balanced Th1 and Th2 immune response to specific antigen. Eur. J. Immunol 37: 1538-1547. (Pubitemid 46939489)
9. Song M, Hong HA, Huang JM, Colenutt C, Khang DD, et al. (2012) Killed Bacillus subtilis spores as a mucosal adjuvant for an H5N1 vaccine. Vaccine 30: 3266-3277.
10. Cutting SM (2011) Bacillus probiotics. Food Microbiol 28: 214-220.
11. Tavares MB, Silva BM, Cavalcante RCM, Souza RD, Luiz WB, et al. (2010) Induction of neutralizing antibodies in mice immunized with an amino-terminal polypeptide of Streptococcus mutans P1 protein produced by a recombinant Bacillus subtilis strain. FEMS Immunol Med Microbiol 59: 131-142.
12. Amuquni H, Tzipori S (2012) Bacillus subtilis: a temperature resistant and needle free delivery system of immunogens. Hum Vaccin Immunother 8: 979-986.
13. Paccez JD, Nguyen HD, Luiz WB, Ferreira RCC, Sbrogio-Almeida ME, et al. (2007) Evaluation of different promoter sequences and antigen sorting signals on the immunogenicity of Bacillus subtilis vaccine vehicles. Vaccine 25: 4671-4680. (Pubitemid 46755459)
14. Negri A, Potocki W, Iwanicki A, Obuchowski M, Hinc K (2013) Expression and display of Clostridium difficile protein FliD on the surface of Bacillus subtilis spores. J Med Microbiol 62: 1379-1385.
15. Nicholson WL, Munakata H, Horneck G, Melosh HJ, Setlow P (2000) Resistance of Bacillus endospores to extreme terrestrial and extraterrestrial environments. Microbiol Mol Biol Rev 64: 548-572.
16. Li X, Xu W, Xiong S (2012) A novel tuberculosis DNA vaccine in an HIV-1 p24 protein backbone confers protection against Mycobacterium tuberculosis and simultaneously elicits robust humoral and cellular responses to HIV-1. Clin Vaccine Immunol 19: 723-730.
17. Bozzaco L, Yu H, Dengjel J, Trumpfheller C, Zebroski HA 3rd, et al. (2012) Strategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV gag p24 protein. PLoS One 7: e41897. doi: 10.1371/journal.pone. 0041897.
18. Wehrl W, Niederweis M, Schumann W (2000) The FtsH protein accumulates at the septum of Bacillus subtilis during cell division and sporulation. J Bacteriol 182: 3870-3873. (Pubitemid 30413046)
19. Deuerling E, Paeslack B, Schumann W (1995) The ftsH gene of Bacillus subtilis is transiently induced after osmotic and temperature upshift. J Bacteriol 177: 4105-4112.
20. Tavares MB, Souza RD, Luiz WB, Cavalcante RCM, Casaroli C, et al. (2013) Bacillus subtilis endospores at high purity and recovery yields: optimization of growth conditions and purification method. Curr Microbiol 66: 279-285.
21. Aida Y, Pabst MJ (1990) Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 132:191-195. (Pubitemid 20281877)
22. Breyhan H, Wirths O, Duan K, Marcello A, Retting J, et al. (2009) APP/PS1KI bigenic mice develop early synaptic deficits and hippocam pus atrophy. Acta Neuropathol 117: 667-685.
23. Liard C, Munier S, Arias M, Joulin-Giet A, Bonduelle O, et al. (2011) Targeting of HIV-p24 particle based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine 29: 6379-6391.
24. Tagliamonte M, Marasco D, Ruggiero A, De Stradis A, Tornesello ML, et al. (2012) HIV p24 as scaffold for presenting conformational HIV Env antigens. PLoS One 7: e43318. doi: 10.1371/journal.pone.0043318.
25. Zanoni I, Ostuni R, Capuano G, Collini M, Caccia M, et al. (2009) CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature 460: 264-268.
26. Marim FM, Silveira TN, Lima DSJ, Zamboni DS (2010) A method for generation of bone marrow-derived macrophages from cryopreserved mouse bone marrow cells. PLoS One 5: e15263. doi: 10.1371/journal.pone.0015263.
27. Amorim JH, Diniz MO, Cariri FA, Rodrigues JF, Bizerra RS, et al. (2012) Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. Vaccine 5: 837-845.
28. Visciano ML, Tangliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L (2012) Effects of adjuvants on IgG subclasses elicited by virus-like particles. J. Tranl. Med 10:4. doi: 10.1186/1479-5876-10-4.
29. Fierens K, Kool M (2012) The mechanism of adjuvanticity of aluminium-contaning formulas. Curr Pharm Des 18: 2305-2313.
30. Rodrigues JF, Mathias-Santos C, Sbrogio-Almeida ME, Amorim JH, Cabrera-Crespo J, et al. (2011) Functional diversity of heat-labile toxin (LT) produced by enterotoxigenic Escherichia coli: differential enzymatic and immunological activities of LT1 (hLT) and LT4 (pLT). J Biol Chem 286: 5222-5233.
31. Christmas P (2010) Toll-Like Receptors: Sensors that Detect Infection. Nature Education 3: 85.
32. Huang JM, La Ragione RM, Nunez A, Cutting SM (2008) Immunostimulatory activity of Bacillus spores. FEMS Immunol Med Microbiol 53: 195-203. (Pubitemid 351832187)
33. Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A (2004) Innate immune response in Th1- and Th2-dominant mouse strains. Shock 22: 460-466. (Pubitemid 39472571)